iRhythm Holdings Completes Acquisition of VitalConnect

Key Facts

1iRhythm Holdings announced the completion of its previously disclosed acquisition of VitalConnect, a leader in wearable biosensor technology.

iRhythm Holdings announced the completion of its previously disclosed acquisition of VitalConnect, a leader in wearable biosensor technology. GlobeNewswire reported that the purchase consideration consisted of $237.5 million in cash, funded from iRhythm's balance sheet, and up to 423,334 shares issued in connection with the closing.

The acquisition aims to integrate VitalConnect’s platform, which offers up to 30-day patient monitoring and the capability to track 11 physiological parameters, into iRhythm's broader cardiac monitoring and intelligence strategy. The company stated that the move is expected to enhance its revenue growth rate while preserving its adjusted EBITDA margin target of 15% for 2027.

iRhythm is scheduled to provide updated 2026 financial guidance, inclusive of VitalConnect, during its third quarter earnings call on November 5, 2026.